MVR-T3011
- Generic Name
- MVR-T3011
- Drug Type
- Biotech
- Background
MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.
A Study of T3011 in Patients With BCG-Unresponsive High Risk NMIBC
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- ImmVira Pharma Co. Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT06971614
- Locations
- 🇺🇸
Advanced Urology Medical Offices, Los Angels, California, United States
A Clinical Study of T3011 in Subjects With Advanced Melanoma
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06214156
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06200363
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06200376
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath